> Sharp increase in operating revenue: up 32% at €15.0 million, driven by sales growth of 58% to €9.2 million.

> Higher operating expenses reflecting the more rapid development of the Service business and increased R&D spending for Partnership and Licensing activities

> Cash position of €9.8 million at 30 June 2018

Access our innovation platform via three offerings: as a service, under a partnership or based on a licensing arrangement

Thanks to its precision medicine platform, Oncodesign is able to orient at a very early stage its research and the development of innovative therapeutic solutions for resistant and unresponsive diseases

For over 20 years, Oncodesign has invested in translational research technologies to bring valuable innovation into the initial phases of the Drug Discovery process.